Beyond the Trend Arrow: Potential Value of Artificial Intelligence-Supported Glucose Predictions for People with Type 1 Diabetes Using Continuous Glucose Monitoring Systems.

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Sufyan Hussain, William Polonsky, Renza Scibilia, Timor Glatzer
{"title":"Beyond the Trend Arrow: Potential Value of Artificial Intelligence-Supported Glucose Predictions for People with Type 1 Diabetes Using Continuous Glucose Monitoring Systems.","authors":"Sufyan Hussain, William Polonsky, Renza Scibilia, Timor Glatzer","doi":"10.1089/dia.2025.0293","DOIUrl":null,"url":null,"abstract":"<p><p>Advances in diabetes technologies such as continuous glucose monitoring (CGM) have provided significant opportunities to improve glycemic and quality-of-life outcomes for people with type 1 diabetes (T1D). The ambulatory glucose profile and the introduction of glucose thresholds helped a lot to identify patterns, which was the first step toward improving hyper-and hypoglycemia management. Despite these innovations, the relentless burden of day-to-day T1D management continues to be a challenge for individuals and their families. In particular, hypoglycemia remains a significant cause of morbidity and mortality, as well as a barrier to achieving optimal glycemia, contributing to anxiety, fear, worry, and distress. Algorithm developments have led to CGM device-based thresholds and predictive alarms to warn individuals of impending hypoglycemia. More recent developments with artificial intelligence technology now allow for forecasting glucose trends and values over longer time frames, thereby aiding therapy decision-making. In this article, we focus on hypoglycemia and summarize recent developments in glucose prediction from CGM devices. While not intended to be a comprehensive review, we provide an update, highlight anticipated developments, and speculate on potential pitfalls and the potential value from medical, psychosocial, and lived experience perspective.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2025.0293","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Advances in diabetes technologies such as continuous glucose monitoring (CGM) have provided significant opportunities to improve glycemic and quality-of-life outcomes for people with type 1 diabetes (T1D). The ambulatory glucose profile and the introduction of glucose thresholds helped a lot to identify patterns, which was the first step toward improving hyper-and hypoglycemia management. Despite these innovations, the relentless burden of day-to-day T1D management continues to be a challenge for individuals and their families. In particular, hypoglycemia remains a significant cause of morbidity and mortality, as well as a barrier to achieving optimal glycemia, contributing to anxiety, fear, worry, and distress. Algorithm developments have led to CGM device-based thresholds and predictive alarms to warn individuals of impending hypoglycemia. More recent developments with artificial intelligence technology now allow for forecasting glucose trends and values over longer time frames, thereby aiding therapy decision-making. In this article, we focus on hypoglycemia and summarize recent developments in glucose prediction from CGM devices. While not intended to be a comprehensive review, we provide an update, highlight anticipated developments, and speculate on potential pitfalls and the potential value from medical, psychosocial, and lived experience perspective.

超越趋势箭头:使用连续血糖监测系统对1型糖尿病患者进行人工智能支持的血糖预测的潜在价值。
糖尿病技术的进步,如连续血糖监测(CGM),为改善1型糖尿病患者的血糖和生活质量提供了重要的机会。动态血糖谱和葡萄糖阈值的引入对识别血糖模式有很大帮助,这是改善高血糖和低血糖管理的第一步。尽管有这些创新,日常T1D管理的繁重负担对个人及其家庭来说仍然是一个挑战。特别是,低血糖仍然是发病率和死亡率的重要原因,也是达到最佳血糖的障碍,导致焦虑、恐惧、担心和痛苦。算法的发展导致了基于CGM设备的阈值和预测性警报,以警告个人即将发生的低血糖。人工智能技术的最新发展现在可以预测更长时间框架内的血糖趋势和值,从而帮助治疗决策。在这篇文章中,我们主要关注低血糖,并总结了CGM设备在血糖预测方面的最新进展。虽然不是一个全面的回顾,我们提供了一个更新,突出了预期的发展,并从医学、社会心理和生活经验的角度推测潜在的缺陷和潜在的价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信